The Hoffmann Lab is focused on reducing TB and HIV morbidity and mortality in the low and middle income settings through behavioral and implementation science approaches. Work has focused on understanding individual-level behavior towards linkage to care and continued care engagement for HIV and TB and using this knowledge to develop approaches to increase HIV testing, linkage to care, HIV viral load suppression, and retention in care. Other work has focused on health system strategies to improve service delivery and improve adherence to best practice to guidelines-based care. The group's research includes work on the general population, corrections inmates and ex-inmates, men at risk for HIV, and recently hospitalized individuals. Most of the research has been in South Africa and elsewhere in sub-Saharan Africa.

Research in the Hansoti Lab centers on the intersection of public health interventions for vulnerable populations and emergency department care. The lab employs implementation science methodologies, with a particular emphasis on mixed-methods research to design, develop, and evaluate innovative, evidence-based strategies that support socially vulnerable patients.

In South Africa, the team is pioneering strategies to enhance HIV prevention and intervention delivery within emergency departments, focusing on improving HIV service delivery for patients missed within the health system and delivering preventative care strategies to patients at high risk of HIV acquisition. These efforts are concentrated at Tygerberg Hospital and Gugulethu Clinic, in partnership with the Desmond Tutu HIV Foundation.

Domestically, the lab conducts research on opioid use disorder (OUD), specifically addressing post-discharge health system challenges related to linkage to care and retention for patients prescribed medications for opioid use disorder (MOUD). This includes addressing social determinants of health to strengthen HIV services for patients who present to the ED.

Additionally, Dr. Hansoti has a dedicated focus on surveillance strategies for high-consequence pathogens in emergency departments. She serves as the Principal Investigator for the Clinical Characterization Protocol for Severe Emerging Infections (CCPSEI) and manages cohorts for both COVID-19 and mpox, in collaboration with experts in public health, epidemiology, and infectious diseases from the Johns Hopkins School of Public Health.

The David Dowdy Lab conducts research in the field of infectious disease epidemiology. We use an interdisciplinary approach that involves infectious disease modeling, health economics, classical epidemiology, and operational and implementation science. Much of our work explores the diagnosis and treatment of tuberculosis. We also have a longstanding interest in “translational epidemiology,” with a goal of developing methods to help medical professionals who use epidemiological data make decisions that are in the best interest of patients and public health.

Our IndoUS team, based both in Baltimore and in India, specializes in international clinical research (cohort studies and clinical trials), public health implementation science and education in infectious diseases, HIV/AIDS, tuberculosis (TB), vaccine preventable illnesses, antimicrobial resistant infections, and more recently COVID. Since 2003, our work has been focused primarily on India, where we are engaged in several Indo-JHU and international research collaborations. We partner with several leading medical and research institutions in India (e.g. BJGMC, DY Patil, Hinduja Hospital, KEM, Bharati Vidyapeeth, NIRT, JIPMER, CMC, Medanta, IISER, YRG, IIT), as well as others in sub-Saharan Africa, US and Brazil. We are actively involved in the following consortia: 1) Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. 2) RePORT International TB Research Consortium, a multilateral global consortia for TB research, 3) US NIH funded multi-country HIV and TB trials consortia of the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT) Network, 4) NIH and AmFAR funded IeDea HIV/TB Working Group and the Treat Asia-IeDEA HIV and TB epidemiology databases, and 5) CDC SHEPHERD AMR studies. Our group has been awarded research grants from the US NIH, US CDC, UNITAID, Indian government, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond.